Welcome to our Knowledge Hub

The life science tools sector, particularly bioreactor technologies, is emerging as a high-growth investment frontier in Europe, combining scientific innovation with robust market dynamics. Driven by pandemic-era acceleration and sustained demand for biopharmaceuticals, this sector offers compelling opportunities for venture capital (VC) and institutional investors. Here's why bioreactors and related technologies are poised to deliver strong returns while advancing global hea

Bioreactors are essential tools in biotechnology, enabling controlled environments for cell culture, fermentation, and metabolite production. Their role is crucial in biopharmaceutical manufacturing, regenerative medicine, and large-scale cell expansion. As bioprocessing demands grow, bioreactor scale-up becomes a key challenge, ensuring that laboratory-developed processes translate effectively into industrial-scale production.

In recent years, Germany’s role in biotech has evolved, particularly in cell and gene therapy manufacturing, where its strong GMP expertise is both an asset and a challenge. While Germany remains a key hub for innovation, complex bureaucracy, extensive documentation requirements, and rigid GMP standards have made scaling advanced therapies slow and costly.

Advanced therapies like cell-based therapies have emerged as a promising field in regenerative medicine, offering novel treatment approaches for conditions such as cancer, autoimmune diseases, and degenerative disorders. One critical distinction in these therapies is whether the cells come from the patient themselves (autologous) or from a donor (allogeneic). Both approaches have unique benefits and limitations, impacting their clinical application and scalability.

Sustainability has long been considered a "nice-to-have" in biotech and pharma - but this is changing fast. With the advent of binding regulations like the European Green Deal and its global counterparts, sustainability is moving from corporate responsibility to legal obligation.

4.4% of the global net emissions are produced by the healthcare sector. What does it need for the sector to become more sustainable?